Fingolimod hydrochloride
- CAS No.
- 162359-56-0
- Chemical Name:
- Fingolimod hydrochloride
- Synonyms
- FTY720;Fingolimod HCl;Gilenya;2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride;Fin;FTY720 . HCl;Fingolimod HC;FingoliMod FTY120;limod hydrochloride;FTY720 HYDROCHLORIDE
- CBNumber:
- CB4244536
- Molecular Formula:
- C19H34ClNO2
- Molecular Weight:
- 343.93
- MDL Number:
- MFCD00939512
- MOL File:
- 162359-56-0.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Melting point | 102-107°C |
|---|---|
| storage temp. | -20°C |
| solubility | water: soluble10mg/mL, clear |
| form | powder |
| color | white to beige |
| biological source | synthetic |
| Water Solubility | water: 10mg/mL, clear |
| Merck | 14,4083 |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months. |
| InChI | InChI=1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H |
| InChIKey | SWZTYAVBMYWFGS-UHFFFAOYSA-N |
| SMILES | C1(C=CC(CCCCCCCC)=CC=1)CCC(N)(CO)CO.Cl |
| CAS DataBase Reference | 162359-56-0(CAS DataBase Reference) |
| EWG's Food Scores | 1 |
| FDA UNII | G926EC510T |
| UNSPSC Code | 41116107 |
| NACRES | NA.77 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|---|---|
| Signal word | Warning |
| Hazard statements | H373 |
| Precautionary statements | P260-P314-P501 |
| target organs | Immune system |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38-52/53 |
| Safety Statements | 26-61 |
| WGK Germany | 3 |
| RTECS | TY3130000 |
| HS Code | 29221990 |
| Storage Class | 11 - Combustible Solids |
| Hazard Classifications | STOT RE 2 |
| Toxicity | LD50 orally in rats: 300-600 mg/kg (Troncoso) |
Fingolimod hydrochloride price More Price(112)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | SML0700 | FTY720 ≥98% (HPLC) | 162359-56-0 | 5mg | $81.7 | 2026-04-30 | Buy |
| Sigma-Aldrich | SML0700 | FTY720 ≥98% (HPLC) | 162359-56-0 | 25mg | $335 | 2026-04-30 | Buy |
| Sigma-Aldrich | PHR2790 | Fingolimod Hydrochloride | 162359-56-0 | 500MG | $1270 | 2026-04-30 | Buy |
| Sigma-Aldrich | 1270480 | Fingolimod Hydrochloride United States Pharmacopeia (USP) Reference Standard | 162359-56-0 | 300MG | $3790 | 2026-04-30 | Buy |
| TCI Chemical | F1018 | Fingolimod Hydrochloride >98.0%(HPLC)(T) | 162359-56-0 | 200mg | $139 | 2026-04-30 | Buy |
Fingolimod hydrochloride Chemical Properties, Uses, Production
Oral drug for the treatment of multiple sclerosis
Fingolimod hydrochloride is the first oral drug for the treatment of multiple sclerosis. It is successfully developed by the pharmaceutical company Novartis, and it has been approved for marketing by the US Food and Drug Administration (FDA). The recommended dose is 0.5mg once a day for oral administration.
Multiple sclerosis is a debilitating neurological disease that can cause the patient to lose a sense of balance, appear muscle spasms and other movement disorders. The disease has been treated with injectable drugs. This kind of medication brought great inconvenience to patients.
Fingolimod is a sphingosine-l-phosphate (S1PR) receptor modulator. After phosphorylation, It is bound to s1P receptor that is on the surface of lymphocyte, which will change lymphocyte migration, and promote cells into the lymphatic tissue, and prevent lymphocytes from leaving the lymphoid tissue and get into the graft. Thereby, it will prevent these cells from infiltrating the central nervous system (CNS), which achieves the effect of immunosuppression. According to the drug's introduction, drugmaker Novartis said that this process of pharmacological effects is reversible. If medication is stopped, the level of lymphocytes in circulating system will return to normal.
The above information is edited by the chemicalbook of Kui Ming.
Description
Approved by the U.S. FDA in September 2010, fingolimod (also referred to as FTY720) is the first approved oral therapy for the relapsing-remitting form ofmultiple sclerosis (RRMS). Because of fingolimod’s structural resemblance to sphingosine, a metabolite of sphingolipids that constitutes the cell membrane of all eukaryotic cells, it was hypothesized that fingolimod may be affecting sphingolipid metabolism in cells. A series of elegant in vitro and in vivo studies confirmed that fingolimod is converted to (S)-fingolimod phosphate primarily by sphingosine kinase- 2 and that (S)-fingolimod phosphate mediates multiple biological processes by binding to novel GPCR’s referred to as sphingosine-1-phosphate (S1P) receptors. S1P receptors are divided into five subtypes, S1P1–5, which have varying tissue and cellular distribution. S1P1–3 receptors are ubiquitously expressed in the immune, cardiovascular, and central nervous systems, S1P4 is restricted to the hematopoietic system, and S1P5 is mostly localized in the white matter of CNS. S1P1–3 receptors play important roles in endothelial barrier function, maintaining vascular tone, regulating heart rate and allowing for lymphocyte egress fromsecondary lymphoid organs. The functional role of S1P4 is unknown,while the S1P5 receptor is thought to be involved in natural killer cell trafficking and oligodendrocyte function.
Chemical Properties
White Solid
Originator
Yoshitomi Pharmaceutical Industries (now Mitsubishi Tanabe Pharma) (United States)
Uses
A derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb Iscaria sinclarii as well as a structural analogue of Sphingosine. It is a novel immune modulator that prolongs allograft transplant survival in numberour models by inhibitin
Uses
Oral medicine for the treatment of multiple sclerosis
Uses
FTY720 is a derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb Iscaria sinclarii as well as a structural analogue of Sphingosine. FTY720 is a novel immune modulator that prolong s allograft transplant survival in numberour models by inhibiting lymphocyte emigration from lymphoid organs. FTY720 us reported to be phosphorylated by sphingosine kinase to FTY720-P, which has been shown to potently stimulate GTPgS binding activity in S1P-transfected CHO cells (EC50 = 210 pM, 4.9 nM, 4.3 nM, and 1 nM for S1P1, S1P3, S1P4 and S1P5, respectively).
Uses
A cell-permeable aminopropanediol immunosuppressive agent that displays lymphocyte sequestration properties.
Uses
Fingolimod Hydrochloride is a derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb Iscaria sinclarii as well as a structural analogue of Sphingosine. Fingolimod is a novel immune modulator that prolongs allograft transplant survival in numerous models by inhibiting lymphocyte emigration from lymphoid organs. Fingolimod is reported to be phosphorylated by sphingosine kinase to FTY720-P, which has been shown to potently stimulate GTPgS binding activity in S1P-transfected CHO cells (EC50 = 210 pM, 4.9 nM, 4.3 nM, and 1 nM for S1P1, S1P3, S1P4 and S1P5, respectively).
Definition
ChEBI: The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod).
brand name
Gilenya
Biochem/physiol Actions
FTY720 is an immunomodulating drug and sphingosine 1-phosphate (S1P) receptor modulator. Phosphorylation of FTY270 by sphingosine kinase causes S1P1R internalization, which sequesters lymphocytes in lymph nodes, preventing them from taking part in an autoimmune response. Clinically, it has been approved for the treatment of multiple sclerosis (MS). It has also been shown to block and reverse paclitaxel-induced chemotherapy induced peripheral neuropathy (CIPN) through S1PR inhibition as well as inhibit the activity of histone deacetylases in the hippocampus of mouse brains, thereby modulating memory.
Clinical Use
Fingolimod hydrochloride is an immunosuppressive drug developed by Novartis and approved in the U.S., Europe, and Australia in 2010 for the treatment of multiple sclerosis. The structure of fingolimod derives from the naturally-occurring myriocin (ISP-1) metabolite of the fungus I. sinclairii and the aminoalcohol functionality within the drug possesses structural similarity to the sphingosine family of natural products.
Synthesis
Although several convenient preparations of fingolimod (FTY720) have been reported in the literature, the route most closely resembling the process-scale approach is described in the scheme. Friedel-Crafts acylation of commercial toluene derivative 89 with bromoacetyl chloride followed by ethoxide-mediated N-acylated aminomalonate (91) attack onto the resulting -bromoketone 90 gave rise to ketoamide 92 in good overall yield. Next, separate hydride reduction protocols were employed to furnish diol 93. Presumably, triethylsilyl hydride reduced the ketone and both ethyl esters within 92 to the corresponding diacid, which then underwent lithium aluminum hydride treatment to arrive at diol 93. Careful attention to stoichiometry was required to avoid over reduction of amide 93, which was critical to achieve high-yielding (76%) salt formation of fingolimod HCl (VI) through the use of 6 N ethanolic hydrochloric acid.
target
COX | PGE | Histamine Receptor | PAK | p21 | S1P
storage
+4°C
References
[1] V. BRINKMANN. The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors*[J]. The Journal of Biological Chemistry, 2002, 10 1: 21453-21457. DOI:10.1074/jbc.c200176200
[2] ANNA MARIA WOLF. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo.[J]. Journal of immunology, 2009, 183 6: 3751-3760. DOI:10.4049/jimmunol.0901011
[3] ANTHONY O AWOJOODU. Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110 34: 13785-13790. DOI:10.1073/pnas.1221309110
[4] CHIBA K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors[J]. Pharmacology & Therapeutics, 2005, 108 3: Pages 308-319. DOI:10.1016/j.pharmthera.2005.05.002
Fingolimod hydrochloride Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Suzhou Zehou Biotechnology Co. , Ltd. | 0512-68716880 19984816880 | sales@growingchem.com | China | 229 | 64 |
| Hefei HomeSunshine Pharmaceutical Technology Co., Ltd. | 0551-65523315 17705606359 | errol@homesunshinepharma.com | China | 64 | 58 |
| Nanjing Chemipioneer Pharma& Tech Co., LTD | 025-52643182 13914798241; | zhoulq@chemipioneer.com.cn | China | 92 | 62 |
| J & K SCIENTIFIC LTD. | 18210857532 18210857532 | jkinfo@jkchemical.com | China | 96815 | 76 |
| Chembest Research Laboratories Limited | 021-20908456 | sales@BioChemBest.com | China | 5996 | 61 |
| TCI (Shanghai) Development Co., Ltd. | 021-67121386 | Sales-CN@TCIchemicals.com | China | 24512 | 81 |
| Shijiazhuang Sdyano Fine Chemical Co., Ltd. | 0311-89250318 13582355795 | master@sjzsdyn.com | China | 2776 | 65 |
| Adamas Reagent, Ltd. | 400-6009262 15618770481 | yhx@titansci.com | China | 14098 | 59 |
| LGM Pharma | 1-(800)-881-8210 | inquiries@lgmpharma.com | United States | 2110 | 70 |
| Shanghai Longsheng chemical Co.,Ltd. | 58099637 13585536065 | sales@shlschem.com | China | 9880 | 59 |
View Latest Price from Fingolimod hydrochloride manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-09-16 | Fingolimod hydrochloride
162359-56-0
|
0.99 | RongNa Biotechnology Co.,Ltd | ||||
 |
2026-09-16 | Fingolimod Hydrochloride
162359-56-0
|
1g | More Than 99% | 100kg/Month | BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | ||
 |
2026-09-16 | Fingolimod Hydrochloride.
162359-56-0
|
1g | More Than 99% | 100kg/Month | BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. |
-
- Fingolimod hydrochloride
162359-56-0
- 0.99
- RongNa Biotechnology Co.,Ltd
-
- Fingolimod Hydrochloride
162359-56-0
- $0.00
- More Than 99%
- BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
-
- Fingolimod Hydrochloride.
162359-56-0
- $0.00
- More Than 99%
- BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
162359-56-0 (Fingolimod hydrochloride) Related Search:
1of4
